| Marc Ross, PA | |
|
401 S Van Brunt St, Englewood, NJ 07631-4604 | |
| (201) 569-2770 | |
| (201) 569-1774 |
| Full Name | Marc Ross |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 21 Years |
| Location | 401 S Van Brunt St, Englewood, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306890249 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363AS0400X | Physician Assistant - Surgical | 25MP00116500 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospital For Special Surgery | New york, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New York Society For The Relief Of Ruptured And Crippled Maintaining | 4789818204 | 96 |
News Archive
American Oriental Bioengineering, Inc. today announced that the Company has launched a new product for the rhinitis and allergy market, called Jingwei Capsules ("Jingwei"). Jingwei will be manufactured by the Company's Boke subsidiary, and will be marketed throughout China utilizing AOBO's distribution network, including the Company's national hospital and pharmacy distribution network.
The pressure for a new product to succeed at launch has never been greater with organizations across the pharmaceutical sector facing pipeline deficits, patent expirations and increasing development costs.
Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH were granted approval of the Marketing Authorization Application for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache by the Federal Institute for Drugs and Medical Devices of Germany (BrArM) and the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA).
Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for the Quad, a complete single-tablet HIV regimen containing elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate.
Membrane proteins are the "gatekeepers" that allow information and molecules to pass into and out of a cell. Until recently, the microscopic study of these complex proteins has been restricted due to limitations of "force microscopes" that are available to researchers and the one-dimensional results these microscopes reveal.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marc Ross, PA 401 S Van Brunt St, Englewood, NJ 07631-4604 Ph: (201) 569-2770 | Marc Ross, PA 401 S Van Brunt St, Englewood, NJ 07631-4604 Ph: (201) 569-2770 |
News Archive
American Oriental Bioengineering, Inc. today announced that the Company has launched a new product for the rhinitis and allergy market, called Jingwei Capsules ("Jingwei"). Jingwei will be manufactured by the Company's Boke subsidiary, and will be marketed throughout China utilizing AOBO's distribution network, including the Company's national hospital and pharmacy distribution network.
The pressure for a new product to succeed at launch has never been greater with organizations across the pharmaceutical sector facing pipeline deficits, patent expirations and increasing development costs.
Aradigm Corporation today announced that Zogenix, Inc. and Desitin Pharmaceuticals GmbH were granted approval of the Marketing Authorization Application for SUMAVEL® DosePro™ (sumatriptan injection) needle-free delivery system for the acute treatment of migraine attacks, with or without aura, and the acute treatment of cluster headache by the Federal Institute for Drugs and Medical Devices of Germany (BrArM) and the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA).
Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for the Quad, a complete single-tablet HIV regimen containing elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate.
Membrane proteins are the "gatekeepers" that allow information and molecules to pass into and out of a cell. Until recently, the microscopic study of these complex proteins has been restricted due to limitations of "force microscopes" that are available to researchers and the one-dimensional results these microscopes reveal.
› Verified 4 days ago
Allison Leigh Luther, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 229 Engle St, Englewood, NJ 07631 Phone: 201-567-8999 | |
Nicole Jennifer Van Dyke, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 401 S Van Brunt St Ste 3, Englewood, NJ 07631 Phone: 201-569-2770 | |
Miss Janine Mary Mansukhani, Physician Assistant Medicare: Medicare Enrolled Practice Location: 350 Engle St Fl 5, Englewood, NJ 07631 Phone: 201-894-3636 | |
Jennie Mayer, PA Physician Assistant Medicare: Medicare Enrolled Practice Location: 350 Engle St, Englewood Hospital, Englewood, NJ 07631 Phone: 201-984-3000 Fax: 610-617-6280 | |
Edwin Salamanca, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 350 Engle Street, Englewood Hospital, Englewood, NJ 07631 Phone: 201-984-3000 Fax: 610-617-6280 | |
Orli Feder, Physician Assistant Medicare: Medicare Enrolled Practice Location: 60 E Linden Ave, Apt: 5a, Englewood, NJ 07631 Phone: 201-873-0086 | |
Ms. Kandice Michelle Rosemond, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 350 Engle St, Englewood, NJ 07631 Phone: 201-894-3636 |